Elderly cancer patients who take erythropoiesis-stimulating agents while undergoing chemotherapy are at increased risk of venous thromboembolism, according to a large epidemiologic study published online Nov. 11 in the Journal of the National Cancer Institute.A total of 11% of the study subjects developed venous thromboembolism. The rate was 14.3% among patients who took erythropoiesis-stimulating agents (ESAs), compared with 9.8% among those who did not. The risk was slightly higher in patients...